The FDA has expanded the indication for Fiasp (insulin aspart injection; Novo Nordisk) 100 Units/mL to include use in insulin infusion pumps to improve glycemic control in adults with type 1 or type 2 ...

Most of the 38 million people living with diabetes in the U.S. use daily injections or insulin pumps to keep glucose at safe levels — but new research suggests that a third option could be just as ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved an expanded label for rapid-acting insulin lispro-aabc injection to include administration via ...

NovoLog (insulin aspart) and Humalog (insulin lispro) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to treat type 1 and type 2 diabetes in certain ...

Insulin pumps can help people with diabetes manage their blood sugar levels. The small, wearable electronic device gives predetermined rates of insulin to your body. You may want to use an insulin ...

The US Food and Drug Administration (FDA) has expanded the indication for the more rapid-acting version of insulin aspart (Fiasp, Novo Nordisk) for use in insulin pumps. Injectable and intravenous ...

Blair Brenner has been an insulin-dependent Type 1 diabetic for more than 40 years and hasn’t always had the disease under control. She’s been hospitalized for diabetic complications and found that ...

Humalog (insulin lispro) and Humulin N (insulin isophane human) are brand-name prescription* medications. They’re approved by the Food and Drug Administration (FDA) to help treat type 1 and type 2 ...

Insulet, MiniMed and Tandem Diabetes Care are all working on systems to take meal announcements out of diabetes management.

Humalog (insulin lispro) is a prescription drug that’s prescribed for diabetes in adults and certain children. The drug comes as a liquid solution for subcutaneous injection or intravenous (IV) ...

The Swiss diabetes hardware company Ypsomed is selling off its insulin pen needle and blood sugar monitoring operations, as it turns its attention toward its drug autoinjectors and digital insulin ...